Prestige Consumer Healthcare (NYSE:PBH) PT Lowered to $103.00

Prestige Consumer Healthcare (NYSE:PBH) had its price objective lowered by analysts at Royal Bank of Canada from $110.00 to $103.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has a “sector perform” rating on the stock. Royal Bank of Canada’s price objective would indicate a potential upside of 74.55% from the company’s current price.

PBH has been the topic of several other reports. TheStreet downgraded shares of Prestige Consumer Healthcare from a “b” rating to a “c+” rating in a report on Thursday, September 7th. BMO Capital Markets cut their price target on shares of Prestige Consumer Healthcare from $124.00 to $117.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, StockNews.com cut shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Monday, November 6th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of “Moderate Buy” and a consensus target price of $90.50.

Prestige Consumer Healthcare Stock Performance

Shares of NYSE:PBH opened at $59.01 on Wednesday. The company has a market capitalization of $2.93 billion, a price-to-earnings ratio of -35.24, a PEG ratio of 1.69 and a beta of 0.57. Prestige Consumer Healthcare has a 12 month low of $55.96 and a 12 month high of $68.54. The firm’s 50-day moving average is $58.75 and its 200 day moving average is $59.54. The company has a current ratio of 2.99, a quick ratio of 1.75 and a debt-to-equity ratio of 0.82.

Insider Transactions at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 2,540 shares of the company’s stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $58.92, for a total value of $149,656.80. Following the completion of the sale, the senior vice president now owns 15,934 shares of the company’s stock, valued at approximately $938,831.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On Prestige Consumer Healthcare

A number of hedge funds and other institutional investors have recently bought and sold shares of PBH. Advisor Group Holdings Inc. lifted its position in Prestige Consumer Healthcare by 10.9% during the first quarter. Advisor Group Holdings Inc. now owns 3,694 shares of the company’s stock valued at $196,000 after acquiring an additional 363 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Prestige Consumer Healthcare by 10.8% during the first quarter. JPMorgan Chase & Co. now owns 210,242 shares of the company’s stock valued at $11,130,000 after acquiring an additional 20,496 shares during the last quarter. Raymond James & Associates increased its stake in Prestige Consumer Healthcare by 84.8% during the 1st quarter. Raymond James & Associates now owns 9,326 shares of the company’s stock valued at $494,000 after purchasing an additional 4,279 shares in the last quarter. US Bancorp DE increased its stake in Prestige Consumer Healthcare by 67.7% during the 1st quarter. US Bancorp DE now owns 10,237 shares of the company’s stock valued at $541,000 after purchasing an additional 4,132 shares in the last quarter. Finally, HighTower Advisors LLC increased its stake in Prestige Consumer Healthcare by 6.0% during the 1st quarter. HighTower Advisors LLC now owns 5,791 shares of the company’s stock valued at $307,000 after purchasing an additional 330 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.